ATE465753T1 - Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden - Google Patents

Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden

Info

Publication number
ATE465753T1
ATE465753T1 AT03776419T AT03776419T ATE465753T1 AT E465753 T1 ATE465753 T1 AT E465753T1 AT 03776419 T AT03776419 T AT 03776419T AT 03776419 T AT03776419 T AT 03776419T AT E465753 T1 ATE465753 T1 AT E465753T1
Authority
AT
Austria
Prior art keywords
methods
compositions
diseases caused
treating diseases
papilloma virus
Prior art date
Application number
AT03776419T
Other languages
German (de)
English (en)
Inventor
Kathleen Beach
Mary Hedley
Robert Urban
Roman M Chicz
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Application granted granted Critical
Publication of ATE465753T1 publication Critical patent/ATE465753T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT03776419T 2002-10-21 2003-10-16 Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden ATE465753T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42006802P 2002-10-21 2002-10-21
US47148103P 2003-05-15 2003-05-15
PCT/US2003/032705 WO2004037175A2 (en) 2002-10-21 2003-10-16 Compositions and methods for treating human papillomavirus-mediated disease

Publications (1)

Publication Number Publication Date
ATE465753T1 true ATE465753T1 (de) 2010-05-15

Family

ID=32179780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03776419T ATE465753T1 (de) 2002-10-21 2003-10-16 Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden

Country Status (8)

Country Link
US (2) US20060247190A1 (enExample)
EP (1) EP1556513B1 (enExample)
JP (2) JP2006503914A (enExample)
AT (1) ATE465753T1 (enExample)
AU (2) AU2003284239B2 (enExample)
CA (1) CA2502696A1 (enExample)
DE (1) DE60332377D1 (enExample)
WO (1) WO2004037175A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2010572T3 (pl) * 2006-04-19 2014-05-30 Postech Acad Ind Found Białka fuzyjne zawierające polipeptydy HPV i peptydy wzmagające odporność do leczenia i zapobiegania rakowi szyjki macicy
EP2013229A2 (en) * 2006-04-21 2009-01-14 Transgene S.A. Hpv-18-based papillomavirus vaccine
MX2008013488A (es) * 2006-04-21 2008-10-30 Transgene Sa Vacuna de virus de papiloma basado en hpv-16 (virus de papiloma humano 16).
KR101710981B1 (ko) * 2006-07-28 2017-02-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP5707326B2 (ja) * 2008-09-02 2015-04-30 アンティジェン・エクスプレス・インコーポレーテッドＡｎｔｉｇｅｎ Ｅｘｐｒｅｓｓ，Ｉｎｃ． ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法
EP2601968A1 (en) 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
EP2897639A4 (en) 2012-09-21 2016-05-04 Frank Bedu-Addo IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
MX2019011324A (es) 2017-03-23 2020-01-21 Massachusetts Gen Hospital Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
JP7457642B2 (ja) * 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
CN112957461B (zh) * 2021-02-02 2023-01-10 南开大学 一种形貌可控自佐剂宫颈癌多肽疫苗的制备及性能表征方法
WO2024180232A1 (en) * 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Therapeutic hpv vaccines based on validated target epitopes

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76429T1 (de) * 1986-03-21 1992-06-15 Pasteur Institut Bestimmte, von einem papillomavirus-genom abgeleitete dns-sequenzen, deren anwendungen fuer in vitro-diagnostische zwecke und die herstellung von antigenzusammensetzungen.
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US6007806A (en) * 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5753233A (en) * 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5543294A (en) 1991-07-19 1996-08-06 The Trustees Of Columbia University In The City Of New York Polymerase chain reaction/restriction fragment length polymorphism method for the detection and typing of myobacteria
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
AU668384B2 (en) * 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5462520A (en) 1992-08-17 1995-10-31 Genetronics, Inc. Transsurface drug delivery by electrofusion of microbubbles to the tissue surface
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ATE386800T1 (de) * 1993-03-17 2008-03-15 Us Gov Health & Human Serv Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5679509A (en) * 1993-09-28 1997-10-21 University Of New Mexico Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AU5297496A (en) 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US5626161A (en) * 1996-04-29 1997-05-06 Fu Tai Umbrella Works, Ltd. Multiple-fold automatic umbrella with simplified reliable control means
AU733719B2 (en) * 1996-10-23 2001-05-24 Trustees Of The University Of Pennsylvania, The Improved vaccines
US20020103145A1 (en) * 1999-05-19 2002-08-01 Adrian Bot Immunization of infants
JP2001507352A (ja) * 1996-12-20 2001-06-05 メルク エンド カンパニー インコーポレーテッド 組換えパピローマウイルスワクチンの組成物
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
GB9722766D0 (en) 1997-10-28 1997-12-24 British Telecomm Portable computers
JP2002508190A (ja) 1997-12-12 2002-03-19 ダイジーン・コーポレーション 万能収集媒質
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
EP1078092B1 (en) * 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
CA2339817A1 (en) 1998-08-12 2000-02-24 Zycos Inc. Profiling and cataloging expressed protein tags
ES2291039T3 (es) * 1998-09-04 2008-02-16 Sanofi Pasteur Limited Tratamiento del cancer cervical.
CA2276066A1 (en) 1999-03-11 2000-09-11 Zycos Inc. Microparticles for delivery of nucleic acid
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
AU785319B2 (en) * 1999-09-16 2007-01-11 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
WO2001027291A1 (en) * 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
ES2260070T3 (es) 1999-11-19 2006-11-01 Mgi Pharma Biologics, Inc. Metodo en flujo continuo para preparar microparticulas.
CA2410208A1 (en) 2000-06-22 2001-12-27 3M Innovative Properties Company Systems and methods for treating a mucosal surface
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences

Also Published As

Publication number Publication date
AU2003284239B2 (en) 2008-08-21
JP2011121946A (ja) 2011-06-23
JP2006503914A (ja) 2006-02-02
AU2008249148A1 (en) 2008-12-11
US20060247190A1 (en) 2006-11-02
CA2502696A1 (en) 2004-05-06
EP1556513A4 (en) 2007-03-14
EP1556513A2 (en) 2005-07-27
DE60332377D1 (de) 2010-06-10
US20110158952A1 (en) 2011-06-30
AU2003284239A1 (en) 2004-05-13
WO2004037175A3 (en) 2004-07-29
WO2004037175A2 (en) 2004-05-06
EP1556513B1 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
ATE465753T1 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
BR0316758A (pt) Vacinas baseadas em levedura como imunoterapia
EP4248983A3 (en) Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
CY1113394T1 (el) Αντισωματα toy pan-kir2dl νκ υποδοχεα και η χρηση τους στη διαγνωση και τη θεραπεια
EA200601671A1 (ru) Идентификация собственных и чужеродных антигенов, вовлечённых в аутоиммунные заболевания
Corbett et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
JP2012010713A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
BR0317544A (pt) Uso de uma composição que compreende vlps de hpv 16 e hpv 18, e, métodos para induzir uma resposta imune contra um ou mais do grupo de tipos de hpv oncogênicos, para prevenir infecção e/ou doença causada por um ou mais do grupo de tipos de hpv oncogênicos, para prevenir a infecção de uma população de pacientes por um ou mais tipos de hpv, uso de uma mistura de vlps de hpv 16 e hpv18, e, composição de vacina
MX2022012647A (es) Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.
Shi et al. Expressions of Bovine IFN-γ and Foot-and-Mouth Disease VP1 antigen in P. pastoris and their effects on mouse immune response to FMD antigens
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
WO2002077012A3 (en) Human papilloma virus immunoreative peptides
Haruna et al. Local production of broadly cross‐reactive IgE against multiple fungal cell wall polysaccharides in patients with allergic fungal rhinosinusitis.
WO2008109686A3 (en) Non- infectious recombinant virus-like particles and their pharmaceutical applications
Zhang et al. Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum)
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
TW200509964A (en) VP1 of foot-and-mouth disease virus
CN1244804A (zh) 肽基免疫治疗剂
EP4295861A1 (en) New treatment and prevention based on new method for controlling cellular immunity
EP1790332A4 (en) VACCINE FOR ORAL ADMINISTRATION
Riedmann Human vaccines and immunotherapeutics: news

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties